Sapporo, Japan

Hirotoshi Ishiwatari

This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Nitto-Denko Corporation. Active years: 2016-2018.

USPTO Granted Patents = 2 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hirotoshi Ishiwatari: Innovator in Tissue Regeneration

Introduction

Hirotoshi Ishiwatari is a notable inventor based in Japan. He has made significant contributions to the field of regenerative medicine. His work focuses on developing methods to regenerate normal tissue from fibrotic tissue.

Latest Patents

Hirotoshi Ishiwatari holds a patent for a pharmaceutical composition titled "Composition For Regenerating Normal Tissue From Fibrotic Tissue." This invention pertains to a method that utilizes a collagen-reducing substance to facilitate the therapeutic regeneration of normal tissue from fibrotic tissue. Although he has 2 patents, his innovative approach has the potential to impact medical treatments significantly.

Career Highlights

Throughout his career, Ishiwatari has dedicated himself to advancing the understanding of tissue regeneration. His research has opened new avenues for therapeutic applications in regenerative medicine. His work is recognized for its potential to improve patient outcomes in various medical conditions.

Collaborations

Ishiwatari has collaborated with esteemed colleagues, including Yoshiro Niitsu and Akihiro Yoneda. These partnerships have enriched his research and contributed to the development of innovative solutions in the field.

Conclusion

Hirotoshi Ishiwatari is a pioneering inventor whose work in tissue regeneration holds promise for future medical advancements. His contributions to regenerative medicine are noteworthy and reflect his commitment to improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…